MyFinsight
Home
Blog
About
Contact
Download
Download image
Eylea Net Product
Sales
$2,747,800K
(-42.36%↓ Y/Y)
ELYEAHD
$1,636,900K
(36.28%↑ Y/Y)
US
$944,700K
(19.99%↑ Y/Y)
Non Us
$507,500K
(18.16%↑ Y/Y)
ELYEAHDAnd EYLEA-US
$4,384,700K
(-26.53%↓ Y/Y)
LIBTAYONet Product Sales
$1,452,200K
(19.35%↑ Y/Y)
Praluent Net Product
Sales-US
$262,500K
(8.61%↑ Y/Y)
Evkeeza-US
$162,200K
(29.04%↑ Y/Y)
Inmazeb-US
$37,400K
(-51.30%↓ Y/Y)
Other Products
$10,100K
Collaboration Revenue
$7,331,200K
(21.02%↑ Y/Y)
Product
$6,309,100K
(-17.30%↓ Y/Y)
Product And Service
Other
$702,600K
(36.43%↑ Y/Y)
Revenue from contract
with customer
$14,342,900K
(0.99%↑ Y/Y)
Other income
(expense), net
$1,696,600K
(100.92%↑ Y/Y)
Income from operations
$3,577,900K
(-10.34%↓ Y/Y)
Total other income
(expense)
$1,652,800K
(109.43%↑ Y/Y)
Total expenses
$10,765,000K
(5.42%↑ Y/Y)
Interest expense
$43,800K
(-20.65%↓ Y/Y)
Other operating
(income) expense, net
$10,000K
(118.73%↑ Y/Y)
Income before income
taxes
$5,230,700K
(9.43%↑ Y/Y)
Research and development
$5,850,200K
(13.99%↑ Y/Y)
Selling, general, and
administrative
$2,700,000K
(-8.61%↓ Y/Y)
Cost of goods sold and
of collaboration...
$1,140,800K
(4.92%↑ Y/Y)
Cost of goods sold and
of collaboration...
$959,900K
(8.68%↑ Y/Y)
Acquired in-process
research and development
$124,100K
(22.87%↑ Y/Y)
Net income
$4,504,900K
(2.09%↑ Y/Y)
Unrealized gain on debt
securities
$83,000K
(12.77%↑ Y/Y)
Gain (loss) on
foreign currency...
$2,400K
(500.00%↑ Y/Y)
Income tax expense
$725,800K
(97.60%↑ Y/Y)
Comprehensive income
$4,590,300K
(2.33%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)